PFE monthly performance report
Check PFE's monthly returns, drawdown, and seasonality trends — updated every month.
PFE monthly report
—
Key takeaways
- Pfizer (PFE) closed November 2026 at $28.89, down 5.34% for the month and +12.02% over the trailing 12 months.
- Year-to-date, PFE is +16.02%, outperforming the S&P 500 which has returned +10.62% YTD.
- The stock is trading +7.12% versus its 200-day moving average ($26.97), a bullish technical signal.
- Over the past three years, PFE has underperformed the S&P 500 by −71.68%, with a relative strength index reading of 58.2.
- Win rate over the trailing 39 months stands at 38.5% — 15 positive months versus 24 negative months.
Pfizer ended November 2026 at $28.89, posting a monthly return of −5.34%. The S&P 500 returned −0.18% over the same window, leaving relative performance at −5.16%.
The current quarter stands at +1.30% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +7.12% versus the 200-day moving average ($26.97).
Year-to-date, PFE is +16.02% against SPY +10.62%, a gap of +5.40%. The stock is currently −8.11% below its 52-week high, with maximum 3-year drawdown at −31.22%.
| Period | PFE | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.21% | −0.36% | +0.57% |
| 1 Week | −1.70% | +2.59% | −4.30% |
| 1 Month | −5.34% | −0.18% | −5.16% |
| 3 Months | +7.84% | −2.37% | +10.21% |
| 6 Months | +11.29% | +0.83% | +10.46% |
| YTD | +16.02% | +10.62% | +5.40% |
| 12 Months | +12.02% | +12.25% | −0.23% |
| 3 Years | −0.31% | +71.37% | −71.68% |
| Rank | Month | Return |
|---|---|---|
| #1 | Aug 2026 | +13.79% |
| #2 | May 2024 | +11.87% |
| #3 | Jul 2024 | +9.15% |
| #4 | Oct 2026 | +7.01% |
| #5 | Aug 2025 | +6.31% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jun 2026 | −8.02% |
| #2 | Oct 2023 | −7.87% |
| #3 | Apr 2024 | −7.68% |
| #4 | Nov 2024 | −7.39% |
| #5 | Sep 2023 | −6.25% |
| Quarter | Return |
|---|---|
| Q3 2025 | +5.12% |
| Q4 2025 | −2.28% |
| Q1 2026 | +12.77% |
| Q2 2026 | −14.25% |
| Q3 2026 | +18.44% |
| Q4 2026 (QTD) | +1.30% |
| Year | Return |
|---|---|
| 2023 | −43.81% |
| 2024 | −7.85% |
| 2025 | −6.14% |
| 2026 | +16.02% |
| Metric | Value |
|---|---|
| 52-Week High | $31.44 (2026-11-05) |
| 52-Week Low | $23.62 (2026-06-25) |
| Current Price | $28.89 |
| 200-Day Moving Average | $26.97 |
| Price vs 200DMA | +7.12% |
| 3-Year Maximum Drawdown | −31.22% (2025-04-10) |
| Current Drawdown from 52W High | −8.11% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 58.2 |
| 3-Year Excess Return vs S&P 500 | −71.68% |
| RS Peak | 102 (Nov 2023) |
| RS Trough | 48 (Jul 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was PFE's return for this report period?
PFE returned −5.34% in the latest monthly window ending 2026-11-13.
Has PFE outperformed SPY year to date?
YTD PFE: +16.02% vs SPY: +10.62%.
What is PFE's 12-month return?
+12.02% over the trailing 12 months.
Is PFE above or below its 200-day moving average?
Price is +7.12% versus 200DMA ($26.97).
What is the maximum drawdown in the 3-year window?
−31.22% on 2025-04-10.